Nucula Logo CLICK HERE TO REGISTER CLICK HERE TO REGISTER
PROGRAM OVERVIEW

Are your patients at an increased risk of COPD exacerbations?

Join us for an expert-led national broadcast to see the latest clinical evidence for NUCALA in patients with COPD and an eosinophilic phenotype. You will have the opportunity to submit your questions during the live Q&A.

PROGRAM OBJECTIVES

  • Review the role of eosinophils as a biomarker to identify patients with a greater risk of COPD exacerbations

  • Discuss the latest data with NUCALA on the rates of exacerbations in adult patients with COPD and an eosinophilic phenotype

  • Explore the key features of the NUCALA pivotal trials, highlighting the inclusion of a wide population of patients with COPD and a blood eosinophil count ≥150 cells/μL

{REMOTELIVEEVENTS}
Broadcast Schedule

The broadcast will be available at various times throughout the day, depending on your time zone. See the chart below for a complete list of broadcast times.

You may participate in any or all webcast sessions.

Available via

  • Desktop
  • Laptop
  • Tablet
  • Mobile

Broadcast Date: Thursday, June 12, 2025

EASTERN CENTRAL MOUNTAIN PACIFIC
12:15 PM 11:15 AM 10:15 AM 9:15 AM
1:15 PM 12:15 PM 11:15 AM 10:15 AM
2:15 PM 1:15 PM 12:15 PM 11:15 AM
3:15 PM 2:15 PM 1:15 PM 12:15 PM
INTENDED AUDIENCE

This broadcast is intended for US healthcare professionals involved in the treatment of COPD.

INDICATION

NUCALA is indicated for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

Known hypersensitivity to mepolizumab or excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). Discontinue if a hypersensitivity reaction occurs.

Acute Symptoms of Asthma or COPD or Acute Deteriorating Disease

NUCALA should not be used to treat acute symptoms or acute exacerbations of asthma or COPD, or acute bronchospasm.

Opportunistic Infections: Herpes Zoster

Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

ADVERSE REACTIONS

The most common adverse reactions (≥5%) were back pain, diarrhea, and cough.

USE IN SPECIFIC POPULATIONS

The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.

Please see full Prescribing Information and Patient Information for NUCALA.